Login
Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc.

gracetx.com

What Do They Do?

Develops reformulated medicines for rare diseases, including an injectable nimodipine treatment intended for hospitals caring for people with bleeding around the brain caused by a ruptured aneurysm.

Who Are Their Customers?

Hospitals and intensive-care units are potential buyers; hospital administrators and critical- and neuro-intensive-care physicians participate in purchasing decisions for their institutions or units.

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q2 FY2027, the three months to Sep 30, 2026
Net income
▼ −127% (Loss)
vs −$938K in Q2 FY2026

Funding for other candidates The latest report says it will not resume internal funding for its other drug candidates under its current plan, after the older report deferred their development while prioritizing its lead candidate.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support